M. Heider

Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma

F. Bassermann, M. Eiber, J. Calais, 2022, EJNMMI Research.

Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

B. Kuster, S. Lemeer, Anne-Kathrin Garz, 2016, Nature Medicine.

Prognostic value of indoleamine 2,3 dioxygenase in patients with higher‐risk myelodysplastic syndromes treated with azacytidine

K. Götze, F. Bassermann, G. Piontek, 2020, British journal of haematology.

Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.

K. Götze, F. Bassermann, S. Jilg, 2021, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma

B. Kuster, S. Lemeer, Jana Zecha, 2021, Molecular cell.

The OTUD6B‐LIN28B‐MYC axis determines the proliferative state in multiple myeloma

B. Kuster, Susan Klaeger, Jana Zecha, 2022, The EMBO journal.

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

D. Hose, H. Goldschmidt, F. Bassermann, 2021, Blood advances.

Establishment and characterization of a human glioblastoma cell line with a stable karyotype and nullisomy 13.

K. Zang, S. Bernhardt, K. Schwechheimer, 1985, Cancer genetics and cytogenetics.

IMiDs mediate their anti-myeloma activity via destabilization of the CD147/MCT1 complex

M. Heider, 2018 .

Multiple Myeloma: Molecular Pathogenesis and Disease Evolution

F. Bassermann, K. Nickel, M. Heider, 2021, Oncology Research and Treatment.

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

F. Bassermann, S. Müller, M. Wirth, 2022, Blood advances.